VivoSeq
Other

Contrast Agent

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Contrast Agent is an early-stage landscape with 0 programs across 2 companies. The most active players are Bayer, Reveal Pharmaceuticals Inc..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalR

Reveal Pharmaceuticals Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Completed16 · 67%
Recruiting4 · 17%
Unknown status3 · 13%
Terminated1 · 4%

Clinical Trials

Trial Activity

24 trials

High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment
Recruiting·JJohns Hopkins University·Phase 4·NCT05954559·25 enrolled
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Recruiting·NRG Oncology·Phase 1·NCT03997370·350 enrolled
Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT07040865·104 enrolled
Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations
Recruiting·UUniversity Hospital Augsburg·N/A·NCT06965790·400 enrolled
Efficacy of Ultrasound Contrast Agent to Assess Renal Masses
Completed·UUniversity Health Network, Toronto·Phase 2·NCT01062178·167 enrolled
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
Completed·Bayer logoBayer·N/A·NCT05350189·1,602 enrolled
MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
Completed·UUniversity of Ulm·Phase 2·NCT00223548·106 enrolled
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
Completed·—·Phase 1·NCT03173066·1 enrolled
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Completed·Bayer logoBayer·Phase 3·NCT05915728·404 enrolled
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
Completed·PPoint Biomedical·Phase 2/3·NCT00594698·150 enrolled
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
Completed·BBracco Diagnostics, Inc·Phase 4·NCT00289029·400 enrolled
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
Completed·BBracco Diagnostics, Inc·Phase 3·NCT00415805·39 enrolled
Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC
Completed·SSeoul National University Hospital·N/A·NCT04722120·68 enrolled
First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent
Completed·RReveal Pharmaceuticals Inc.·Phase 1·NCT05413668·32 enrolled
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
Completed·Bayer logoBayer·Phase 3·NCT05915702·303 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)